STOCK TITAN

Odyssey Therapeutics (ODTX) Stock Price, News & Analysis

ODTX NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
30 136 sessions, May 8, 2026 to November 19, 2026
Largest daily move
-13% close of October 6, 2026
1-month change
+1.3% closing prices, October 19, 2026 to November 19, 2026

Company Description

Odyssey Therapeutics (NASDAQ: ODTX) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $881.6M.

ODTX has gained 1.3% over the past month. The last closing price was $18.34.

This page collects what Stock Titan holds for ODTX, including price data, latest news, SEC filings, upcoming events, and short interest trends.

Stock Performance

$18.34
-3.37%
-0.64
Last updated: at
+1.3%
Performance 1 month
$881.6M

Odyssey Therapeutics (ODTX) closed at $18.34 on November 19, 2026. Over the past month, the price has gained 1.3%.

See what a $1,000 investment in ODTX would be worth today

Average down calculator for ODTX

ODTX Metrics & Rankings

Price returns through November 19, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Odyssey Therapeutics has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include earnings, clinical trial, conferences, AI. View all ODTX news →

Financial Highlights

Odyssey Therapeutics has not filed a full fiscal year of results yet, so there are no annual figures to show here, and the quarterly figures it has reported so far are on its financials page.

Upcoming Events

H1
2027
H1 2027 Clinical

OD-002 trial start

Initiation of OD-002 Phase 1/2a trial expected in H1 2027; first-in-human study start, sites and protocol details to be announced.
Q1
2027
Q1 2027 Clinical

Preclinical studies completion

OD-003 expected to complete preclinical studies supporting an application to begin human testing in Q1 2027.
H2
2027
H2 2027 Clinical

OD-001 trial results

Topline OD-001 Phase 2b monotherapy and Phase 2a combination induction results expected in H2 2027; timing/webcast to be announced.
H2
2027
H2 2027 Clinical

Phase 2 topline results

Topline induction results for Odyssey's Phase 2b monotherapy and Phase 2a combo trials expected in H2 2027; timing/webcast TBD.
H2
2027
H2 2027 Clinical

Topline induction results

Topline induction results from Phase 2a OD-001 + vedolizumab trial expected in H2 2027 (Jul–Dec 2027); week-12 induction readout.

Odyssey Therapeutics has 5 upcoming scheduled events. The next event, "OD-002 trial start", is expected in H1 2027. Investors can track these dates to stay informed about potential catalysts that may affect the ODTX stock price.

Short Interest History

Last 12 Months

Short interest in Odyssey Therapeutics (ODTX) currently stands at 3.3 million shares, up 2.0% from the previous reporting period, representing 8.9% of the float. Since May 2026, short interest has increased by 3770.1%.

Days to Cover History

Last 12 Months

Days to cover for Odyssey Therapeutics (ODTX) currently stands at 15.4 days, up 24.6% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since May 2026, the figure has increased by 1443%. Across the settlements charted above, it has ranged from 1.0 to 18.7 days.

ODTX Company Profile & Sector Positioning

Odyssey Therapeutics (ODTX) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing ODTX often look at related companies in the same sector, including Prime Medicine, Inc. (PRME), Aktis Oncology, Inc. (AKTS), City Therapeutics, Inc. (CTY), Corvus Pharmaceuticals, Inc. (CRVS), and MeiraGTx Holdings plc (MGTX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ODTX's relative position within its industry.

Frequently Asked Questions

The current stock price of Odyssey Therapeutics (ODTX) is $18.34 as of November 19, 2026.

The market cap of Odyssey Therapeutics (ODTX) is approximately $881.6M. Learn more about what market capitalization means .